JAZZ Strangle Strategy
JAZZ (Jazz Pharmaceuticals plc), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc.
JAZZ (Jazz Pharmaceuticals plc) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $14.45B, a trailing P/E of 482.77, a beta of 0.33 versus the broader market, a 52-week range of 105-243.32, average daily share volume of 934K, a public-listing history dating back to 2007, approximately 3K full-time employees. These structural characteristics shape how JAZZ stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.33 indicates JAZZ has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. The trailing P/E of 482.77 is on the rich side, which tends to correlate with higher earnings-window IV expansion as the market debates whether forward growth supports the multiple.
What is a strangle on JAZZ?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current JAZZ snapshot
As of June 26, 2026, spot at $229.75, ATM IV 34.60%, IV rank 15.45%, expected move 9.92%. The strangle on JAZZ below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 18-day expiry.
Why this strangle structure on JAZZ specifically: JAZZ IV at 34.60% is on the cheap side of its 1-year range, which favors premium-buying structures like a JAZZ strangle, with a market-implied 1-standard-deviation move of approximately 9.92% (roughly $22.79 on the underlying). The 18-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated JAZZ expiries trade a higher absolute premium for lower per-day decay. Position sizing on JAZZ should anchor to the underlying notional of $229.75 per share and to the trader's directional view on JAZZ stock.
JAZZ strangle setup
The JAZZ strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With JAZZ near $229.75, the first option leg uses a $240.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed JAZZ chain at a 18-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 JAZZ shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $240.00 | $5.95 |
| Buy 1 | Put | $220.00 | $2.33 |
JAZZ strangle risk and reward
- Net Premium / Debit
- -$827.50
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$827.50
- Breakeven(s)
- $211.73, $248.28
- Risk / Reward Ratio
- Unbounded
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
JAZZ strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on JAZZ. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | +$21,171.50 |
| $50.81 | -77.9% | +$16,091.71 |
| $101.61 | -55.8% | +$11,011.92 |
| $152.40 | -33.7% | +$5,932.13 |
| $203.20 | -11.6% | +$852.34 |
| $254.00 | +10.6% | +$572.44 |
| $304.80 | +32.7% | +$5,652.23 |
| $355.60 | +54.8% | +$10,732.02 |
| $406.39 | +76.9% | +$15,811.81 |
| $457.19 | +99.0% | +$20,891.60 |
When traders use strangle on JAZZ
Strangles on JAZZ are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the JAZZ chain.
JAZZ thesis for this strangle
The market-implied 1-standard-deviation range for JAZZ extends from approximately $206.96 on the downside to $252.54 on the upside. A JAZZ long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current JAZZ IV rank near 15.45% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on JAZZ at 34.60%. As a Healthcare name, JAZZ options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to JAZZ-specific events.
JAZZ strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. JAZZ positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move JAZZ alongside the broader basket even when JAZZ-specific fundamentals are unchanged. Always rebuild the position from current JAZZ chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on JAZZ?
- A strangle on JAZZ is the strangle strategy applied to JAZZ (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With JAZZ stock trading near $229.75, the strikes shown on this page are snapped to the nearest listed JAZZ chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are JAZZ strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the JAZZ strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 34.60%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$827.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a JAZZ strangle?
- The breakeven for the JAZZ strangle priced on this page is roughly $211.73 and $248.28 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current JAZZ market-implied 1-standard-deviation expected move is approximately 9.92%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on JAZZ?
- Strangles on JAZZ are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the JAZZ chain.
- How does current JAZZ implied volatility affect this strangle?
- JAZZ ATM IV is at 34.60% with IV rank near 15.45%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.